Key facts
- It has raised $2.6M; the latest was Seed Round ($1.9M) in Mar 2025.
- Notable investors include Clarendon Fund Managers, Catalyst (EU), DSW Ventures, Duncreggan Student Village, ICURe — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for StimOxyGen
- ·The full record, as it builds
Funding rounds
No funding rounds for StimOxyGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StimOxyGen
Developer of stimulus-responsive therapeutic systems designed for the treatment of cancer. The company's system offers a nanoparticle formulation that dissolves at a low hydrogen potential and transiently generates oxygen in hypoxic tumors, enabling doctors to meet clinical needs by fueling tumors with oxygen to maximize the therapeutic effects of radiotherapy.
- Sector
- Healthcare
- HQ
- Londonderry, United Kingdom
- Founded
- 2021
- Employees
- 5
- Website
- stimoxygen.com/
- Ownership
- Privately Held (backing)
StimOxyGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StimOxyGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StimOxyGen in its N-PORT filings yet. We sweep new filings monthly.